< Key Hightlight >

The global hepatitis testing market is projected to reach USD 3.6 billion by 2026 from USD 2.8 billion in 2021, at a CAGR of 4.7% during the forecast period. The growth of the global hepatitis testing market is being driven by factors such as the high burden of hepatitis, increasing blood transfusion and donations, benefits of POC instruments and kits, and awareness initiatives on hepatitis. High cost of nucleic acid tests, lack of mandates for nucleic acid tests in developing countries and unfavorable reimbursement scenarios are expected to restrain hepatitis market growth. Emerging markets, rising technological advancements in molecular diagnostics, and growth in the biotechnology and biopharmaceutical industries are expected to offer strong growth opportunities for players in the market. In contrast, changing regulatory landscape, opertationsla barriers and shortage of skilled professionals may challenge market growth to a certain extent. The hepatitis testing market is segmented based on disease type, technology, end user, and region.

“Hepatitis B segment is expected to dominate the market during the forecast period.”

Based on disease type, the hepatitis testing market is segmented into hepatitis B, hepatitis C, and other hepatitis diseases (hepatitis A, D, and E). The hepatitis B segment accounted for the largest share of the hepatitis testing market in 2020. Factors such as the rising prevalence of hepatitis B, availability of a large number of hepatitis B diagnostic tests, and the increasing adoption of nucleic acid tests for HBV diagnosis are driving the growth of this market segment.

“ELISA segment holds highest market share during the forecast period.”

Based on technology, the hepatitis testing market is segmented into enzyme-linked immunosorbent assay (ELISA), rapid diagnostic tests, polymerase chain reaction (PCR), isothermal nucleic acid amplification technology (INAAT), and other technologies (such as sequencing, mass spectrometry, and western blotting). The ELISA segment accounted for the largest share of the hepatitis testing market in 2020. The large share of this segment can primarily be attributed to the wide acceptance of this test in clinical practices to diagnose hepatitis.

“Hospital & Diagnostic Laboratories segment to dominate the market during the forecast period.”

Based on end user, the hepatitis testing market is segmented into hospital & diagnostic laboratories, blood banks, and other end users (academic & government research institutes, nursing homes, and home care settings). In 2020, the hospital & diagnostic laboratories segment accounted for the largest share of the hepatitis testing market. The large share of this segment can be attributed to the large number of hepatitis diagnostic tests carried out in hospitals.

“North America will dominate the market during the forecast period.”

The global hepatitis testing market is segmented into North America (the US and Canada), Europe (Germany, the UK, and the Rest of Europe), Asia Pacific, and Rest of the World. In 2020, North America dominates the global market, and this trend is expected to continue during the forecast period. The large share and high growth of this region can be attributed to the rising prevalence of hepatitis and increased research and clinical trials for hepatitis testing in the US.

The primary interviews conducted for this report can be categorized as follows:

• By Company Type -Tier 1: 32%,Tier 2: 42% and Tier 26%

• By Designation - C-level:23%, D-level:35%, and Others:42%

• By Region - North America:39%, Europe:25%, Asia Pacific:26%, and Rest of the World: 10%

List of Companies Profiled in the Report 

• F. Hoffmann-La Roche Ltd. (Switzerland)

• Abbott Laboratories (US)

• Siemens Healthineers AG (Germany)

• Bio-Rad Laboratories, Inc. (US)

• Danaher Corporation (US)

• QIAGEN (Netherlands)

• bioMérieux SA (France)

• DiaSorin S.P.A. (Italy)

• Ortho Clinical Diagnostics (US)

• MedMira Inc. (Canada)

• Fujirebio US, Inc. (Japan)

• Grifols, S.A. (Spain)

• Orasure Technologies (US)

• GenMark Diagnostics Inc. (US)

• Vela Diagnostics (Singapore)

• Epitope Diagnostics (US)

• Trivitron Healthcare (India)

• Meril Life Sciences Pvt. Ltd. (India)

• geneOmbio Technologies Pvt. Ltd. (India)

• Molbio Diagnostics Pvt. Ltd. (India)

Research Coverage:

This report provides a detailed picture of the global hepatitis testing market. It aims at estimating the size and future growth potential of the market across different segments, such as disease type, technology, end user and region. The report also analyzes factors (such as drivers, restraints,opportunities and challenges) affecting market growth. It evaluates the opportunities in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micromarkets with respect to their growth trends, prospects, and contributions to the total hepatitis testing market. The report forecasts the revenue of the market segments with respect to four major regions.

Reasons to Buy the Report: 

The report provides insights on the following pointers:

• Market Penetration: Comprehensive information on hepatitis testing offered by the top 20 players in the hepatitis testing market. The report analyses the hepatitis testing market by disease type, technology, end user and region.

• Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various hepatitis testing across key geographic regions.

• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the hepatitis testing market.

• Competitive Assessment: In-depth assessment of market ranking and strategies of the leading players in the hepatitis testing market.